Nikaido Mitsuhiro, Kakiuchi Nobuyuki, Miyamoto Shin'ichi, Hirano Tomonori, Takeuchi Yasuhide, Funakoshi Taro, Yokoyama Akira, Ogasawara Tatsuki, Yamamoto Yoshihiro, Yamada Atsushi, Setoyama Takeshi, Shimizu Takahiro, Kato Yukari, Uose Suguru, Sakurai Takaki, Minamiguchi Sachiko, Obama Kazutaka, Sakai Yoshiharu, Muto Manabu, Chiba Tsutomu, Ogawa Seishi, Seno Hiroshi
Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Department of Pathology and Tumor Biology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Gastric Cancer. 2021 Sep;24(5):1102-1114. doi: 10.1007/s10120-021-01191-8. Epub 2021 May 7.
In Helicobacter pylori (Hp)-uninfected individuals, diffuse-type gastric cancer (DGC) was reported as the most common type of cancer. However, the carcinogenic mechanism of Hp-uninfected sporadic DGC is largely unknown.
We performed whole-exome sequencing of Hp-uninfected DGCs and Hp-uninfected normal gastric mucosa. For advanced DGCs, external datasets were also analyzed.
Eighteen patients (aged 29-78 years) with DGCs and nine normal subjects (28-77 years) were examined. The mutation burden in intramucosal DGCs (10-66 mutations per exome) from individuals aged 29-73 years was not very different from that in the normal gastric glands, which showed a constant mutation accumulation rate (0.33 mutations/exome/year). Unbiased dN/dS analysis showed that CDH1 somatic mutation was a driver mutation for intramucosal DGC. CDH1 mutation was more frequent in intramucosal DGCs (67%) than in advanced DGCs (27%). In contrast, TP53 mutation was more frequent in advanced DGCs (52%) than in intramucosal DGCs (0%). This discrepancy in mutations suggests that CDH1-mutated intramucosal DGCs make a relatively small contribution to advanced DGC formation. Among the 16 intramucosal DGCs (median size, 6.5 mm), 15 DGCs were pure signet ring cell carcinoma (SRCC) with reduced E-cadherin expression and a low proliferative capacity (median Ki-67 index, 2.4%). Five SRCCs reviewed endoscopically over 2-5 years showed no progression.
Impaired E-cadherin function due to CDH1 mutation was considered as an early carcinogenic event of Hp-uninfected intramucosal SRCC. Genetic and clinical analyses suggest that Hp-uninfected intramucosal SRCCs may be less likely to develop into advanced DGCs.
在未感染幽门螺杆菌(Hp)的个体中,弥漫型胃癌(DGC)被报道为最常见的癌症类型。然而,未感染Hp的散发性DGC的致癌机制在很大程度上尚不清楚。
我们对未感染Hp的DGC和未感染Hp的正常胃黏膜进行了全外显子组测序。对于进展期DGC,还分析了外部数据集。
检查了18例DGC患者(年龄29 - 78岁)和9名正常受试者(28 - 77岁)。29 - 73岁个体的黏膜内DGC(每个外显子组10 - 66个突变)的突变负担与正常胃腺中的突变负担没有很大差异,正常胃腺显示出恒定的突变积累率(0.33个突变/外显子组/年)。无偏倚的dN/dS分析表明,CDH1体细胞突变是黏膜内DGC的驱动突变。CDH1突变在黏膜内DGC中(67%)比在进展期DGC中(27%)更频繁。相反,TP53突变在进展期DGC中(52%)比在黏膜内DGC中(0%)更频繁。这种突变差异表明,CDH1突变的黏膜内DGC对进展期DGC形成的贡献相对较小。在16例黏膜内DGC(中位大小,6.5毫米)中,15例DGC为纯印戒细胞癌(SRCC),E - 钙黏蛋白表达降低且增殖能力低(中位Ki-67指数,2.4%)。在内镜下观察2 - 5年的5例SRCC中未显示进展。
由于CDH1突变导致的E - 钙黏蛋白功能受损被认为是未感染Hp的黏膜内SRCC的早期致癌事件。遗传和临床分析表明,未感染Hp的黏膜内SRCC发展为进展期DGC的可能性可能较小。